Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition containing an anti-fungus agent and one active substance selected from carveol, eugenol, thymol, borneol, carvacrol, alpha-ionone and beta-ionone

A technology for antifungal agents, ionones, applied to a formulation comprising an antifungal agent and an active substance selected from the group consisting of carveol, eugenol, thymol, borneol, carvacrol, alpha-ionone and beta-ionone In the field of pharmaceutical compositions, it can solve the problems of life expectancy, shortening and affecting the quality of life of immunosuppressed patients who are difficult to treat

Inactive Publication Date: 2008-05-28
ADVANCED SCIENTIFICS INC
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] For example, in particular, immunosuppressed patients are becoming increasingly difficult to treat and their life expectancy is correspondingly shortened
Furthermore, administration of high doses of therapeutic agents can significantly affect their quality of life

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition containing an anti-fungus agent and one active substance selected from carveol, eugenol, thymol, borneol, carvacrol, alpha-ionone and beta-ionone

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0055] Example 1: Treatment of different albicans with carvacrol-enhanced fluconazole (Fluc P) Bead strain

[0056] In vitro experiments: determination of the minimum fungicidal concentration (MFC) against different strains of Candida albicans

[0057] Experiments were performed with several strains of Candida albicans isolated in a hospital environment from the cavity, vagina and alimentary canal and with different sensitivities. The antifungal agent used was fluconazole, an azole derivative which is one of the most effective and widely used antifungal drugs on the market. The antifungal pharmaceutical composition was prepared by mixing different concentrations of fluconazole with sub-inhibitory concentrations of carvacrol in 0.3 g / l solution or vehicle. The pharmaceutical composition according to the invention is named FLUC-P for enhanced fluconazole. In each case, the antifungal activity was determined with fluconazole alone, or with carvacrol alone, or with the compos...

example 2

[0081] Example 2: Treatment of different white Candida chromosus

[0082] Experiments were performed with several strains of Candida albicans with different sensitivities isolated in a hospital setting. The antifungal agent used was voliconazole, which is an azole derivative and is one of the newest antifungal agents on the market. An antifungal pharmaceutical composition according to the present invention is prepared by mixing different concentrations of voriconazole and sub-inhibitory concentrations of carvacrol in 0.3 g / l solution or vehicle. The pharmaceutical composition according to the invention is named Vorico-P for enhanced voriconazole. In each case, antifungal activity was determined with voriconazole alone, or with carvacrol alone, or with the composition of the invention.

[0083] Table 2 shows the results of static experiments used to determine the minimum inhibitory concentration (MIC) and minimum fungicidal concentration (MFC) in μg / ml.

[0084] Table 2 ...

example 3

[0089] Example 3: Treatment of different white Candida chromosus

[0090] Experiments were performed with several strains of Candida albicans with different sensitivities isolated in a hospital setting. The antifungal agent used was caspofungin from the echinocandin class, which is the newest antifungal agent on the market. An antifungal pharmaceutical composition according to the present invention is prepared by mixing different concentrations of caspofungin and sub-inhibitory concentrations of carvacrol in 0.3 g / l solution or excipient. The pharmaceutical composition according to the invention is named Caspo-P for enhanced caspofungin. In each case, the antifungal activity was determined with caspofungin alone, or with carvacrol alone, or with the composition of the invention.

[0091] Table 3 shows the results of static experiments used to determine the minimum inhibitory concentration (MIC) and minimum fungicidal concentration (MFC) in μg / ml.

[0092] table 3

[00...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a pharmaceutical composition. The pharmaceutical composition of the present invention comprises: at least one first therapeutically active substance selected from carvacrol, thymol, eugenol, borneol, carvacrol, α-ionone, β-ionone and their isomers body and derivatives and mixtures, and at least one second therapeutically active substance which is an antifungal agent.

Description

technical field [0001] The present invention relates to a pharmaceutical composition comprising two therapeutically active substances, one of which exerts a synergistic effect on the other, and to the use of the composition. Background technique [0002] It is known that the efficacy of a therapeutic agent depends on the dose used, which in the case of partial resistance makes it necessary to increase the dose of the therapeutic agent in order to obtain the desired efficacy. Questions of such dose increases leading to adverse effects and acute or chronic toxicity may significantly complicate the condition of the treated patient. [0003] Said partial drug resistance can be transformed into full drug resistance. In this case, increasing the dose no longer had any beneficial therapeutic effect, only toxic effects were observed. Treatment in this case includes changing the therapeutic agent. [0004] This chain of events can repeat itself and lead to the most severe case: co...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61P31/00A61P31/10A61K45/06A61K31/045A61K31/05A61K31/4196
CPCA61K45/06A61K31/05A61K31/045A61K31/4196A61P31/00A61P31/10A61P43/00A61K2300/00
Inventor 阿德南·雷梅尔
Owner ADVANCED SCIENTIFICS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com